title: Can the response to mood stabilizers be predicted in bipolar disorder?
abstract: Bipolar disorder (BD) is a severe chronic multifactorial disease that requires maintenance therapy with mood stabilizers (MS). Even with medications, the rate of response among patients with BD is low and the risk of relapse is high. Therefore, in this context of the urgent need for reliable and reproducible predictors of individual responses to MS, pharmacogenetics research is expected to provide helpful progress. Most pharmacogenetic studies of MS have focused on the response to lithium with several good putative candidate genes but informative results are sparse. There have been few studies on valproate, lamotrigine or atypical antipsychotics. Overall, the results of pharmacogenomics studies have not provided sufficient data to change daily practices in BD significantly and further investigation is warranted to identify highly relevant genetic predictors of response their roles. Although progress still remains to be made, the clinical assessment of a subject including the identification of specific individual phenotypic and pharmacogenetic characteristics is likely to become a powerful instrument for the development of personalized therapies.
authors.affiliation: Pole de Psychiatrie, Centre Expert Bipolaire, Hopital Albert Chenevier, pavillon Hartman, 40, rue de Mesly, 94000 Creteil Cedex, France.
authors.forename: Pierre Alexis
authors.initials: PA
authors.lastname: Geoffroy
authors.affiliation: FondaMental Foundation, Creteil, 94000, France.
authors.forename: Frank
authors.initials: F
authors.lastname: Bellivier
authors.affiliation: Pole de Psychiatrie, Centre Expert Bipolaire, Hopital Albert Chenevier, pavillon Hartman, 40, rue de Mesly, 94000 Creteil Cedex, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Leboyer
authors.affiliation: Pole de Psychiatrie, Centre Expert Bipolaire, Hopital Albert Chenevier, pavillon Hartman, 40, rue de Mesly, 94000 Creteil Cedex, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Etain
mesh_terms: D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D056925:Circadian Rhythm Signaling Peptides and Proteins / Q000378:metabolism*; D056726:Genetic Association Studies / Q000379:methods; D055106:Genome-Wide Association Study; D006801:Humans; D007294:Inositol; D008094:Lithium; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype; D014635:Valproic Acid
chemical_list: D018692:Antimanic Agents; D056925:Circadian Rhythm Signaling Peptides and Proteins; D018377:Neurotransmitter Agents; D007294:Inositol; D014635:Valproic Acid; D008094:Lithium